Champions Oncology, Inc. Forecast, price target & analysts
$8.17
7.68%
yesterday
Nasdaq,
Apr 03, 10:00 pm CET
Champions Oncology, Inc. Target price 2025 - Analyst rating & recommendation
Powered by
Champions Oncology, Inc. Classifications & Recommendation:
Buy
100%
Champions Oncology, Inc. Price Target
| Target Price | $12.00 |
| Price | $8.17 |
| Potential |
46.88%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Champions Oncology, Inc. price target 2026.
The average Champions Oncology, Inc. target price is $12.00.
This is
46.88%
register free of charge
|
|
| A rating was issued by 1 analysts: 1 Analysts recommend Champions Oncology, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Champions Oncology, Inc. stock has an average upside potential 2026 of
46.88%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
Create a premium account to unlock analyst estimates.
Learn more
Powered by
Quarter
Annually
| Apr '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 50.16 | 56.60 |
| 6.89% | 12.84% | |
| EBITDA Margin | -10.07% | 10.51% |
| 333.88% | 204.39% |
1 Analyst has issued a sales forecast Champions Oncology, Inc. 2025 . The average Champions Oncology, Inc. sales estimate is
$56.6m
Unlock
3.40%
lower
Unlock
$56.6m
3.40%
Unlock
$56.6m
3.40%
Unlock
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Champions Oncology, Inc. 2025 . The average Champions Oncology, Inc. EBITDA estimate is
$5.9m
Unlock
31.80%
lower
Unlock
$5.9m
31.80%
Unlock
$5.9m
31.80%
Unlock
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Apr '24 |
2025 Estimates |
|
|---|---|---|
| EV/Sales | 2.06 |
Current Champions Oncology, Inc. Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Dec 12 2024 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Sep 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Dec 12 2024 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Sep 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
